Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,533 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Implantation of dedifferentiated fat cells ameliorated antineutrophil cytoplasmic antibody glomerulonephritis by immunosuppression and increases in tumor necrosis factor-stimulated gene-6.
Utsunomiya K, Maruyama T, Shimizu S, Matsumoto T, Endo M, Kobayashi H, Kano K, Abe M, Fukuda N. Utsunomiya K, et al. Among authors: shimizu s. Stem Cell Res Ther. 2022 Jul 16;13(1):319. doi: 10.1186/s13287-022-03014-8. Stem Cell Res Ther. 2022. PMID: 35842674 Free PMC article.
New limit on the T-violating transverse muon polarization in K+-->pi0mu+nu decays.
Abe M, Aliev M, Anisimovsky V, Aoki M, Asano Y, Baker T, Blecher M, Depommier P, Hasinoff M, Horie K, Igarashi Y, Imazato J, Ivashkin AP, Khabibullin MM, Khotjantsev AN, Kudenko YG, Kuno Y, Lee KS, Levchenko A, Lim GY, Macdonald JA, Mineev OV, Okorokova N, Rangacharyulu C, Shimizu S, Shin YH, Shin YM, Sim KS, Yershov N, Yokoi T; KEK-E246 Collaboration. Abe M, et al. Among authors: shimizu s. Phys Rev Lett. 2004 Sep 24;93(13):131601. doi: 10.1103/PhysRevLett.93.131601. Epub 2004 Sep 21. Phys Rev Lett. 2004. PMID: 15524701
Current status of the cost burden of first-line systemic treatment for patients with advanced hepatocellular carcinoma in Japan, 2021-22.
Imaoka H, Sasaki K, Machida R, Nagano H, Satoi S, Ikeda M, Kobayashi S, Yamashita T, Okusaka T, Ido A, Hatano E, Miwa H, Ueno M, Nakao K, Shimizu S, Kuramochi H, Sakamori R, Tsumura H, Okano N, Shioji K, Shirakawa H, Akutsu N, Tsuji K, Ishii H, Umemoto K, Asagi A, Ueno M; JCOG Hepatobiliary and Pancreatic Oncology Group. Imaoka H, et al. Among authors: shimizu s. Jpn J Clin Oncol. 2024 Jun 7:hyae048. doi: 10.1093/jjco/hyae048. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 38843879
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, Kitano M, Lee CK, Kim JW, Chen MH, Suksombooncharoen T, Ikeda M, Lee MA, Chen JS, Potemski P, Burris HA 3rd, Ostwal V, Tanasanvimon S, Morizane C, Zaucha RE, McNamara MG, Avallone A, Cundom JE, Breder V, Tan B, Shimizu S, Tougeron D, Evesque L, Petrova M, Zhen DB, Gillmore R, Gupta VG, Dayyani F, Park JO, Buchschacher GL Jr, Rey F, Kim H, Wang J, Morgan C, Rokutanda N, Żotkiewicz M, Vogel A, Valle JW. Oh DY, et al. Among authors: shimizu s. Lancet Gastroenterol Hepatol. 2024 May 29:S2468-1253(24)00095-5. doi: 10.1016/S2468-1253(24)00095-5. Online ahead of print. Lancet Gastroenterol Hepatol. 2024. PMID: 38823398
4,533 results